SpringWorks EU approval would enhance strategic value, says Evercore

Evercore ISI analyst Cory Kasimov says SpringWorks Therapeutics (SWTX)’ Ogsiveo is on today’s agenda for the European Medicines Agency’s Committee for Medicinal Products for Human Use meeting. The firm remains confident in a positive opinion, which it anticipates on Friday. SpringWorks is an emerging multi-product story and Ogsiveo’s potential geographic expansion into Europe would enhance the company’s overall strategic value, especially for European companies, the analyst tells investors in a research note. Evercore keeps an Outperform rating on SpringWorks with a $65 price target The stock in late morning trading is up 6% to $39.38.